| Literature DB >> 31324811 |
Bingjun Sun1, Cong Luo1, Xuanbo Zhang1, Mengran Guo1, Mengchi Sun1, Han Yu1, Qin Chen2, Wenqian Yang1, Menglin Wang1, Shiyi Zuo1, Pengyu Chen3, Qiming Kan4, Haotian Zhang4, Yongjun Wang1, Zhonggui He1, Jin Sun5.
Abstract
Tumor cells are characterized as redox-heterogeneous intracellular microenvironment due to the simultaneous overproduction of reactive oxygen species and glutathione. Rational design of redox-responsive drug delivery systems is a promising prospect for efficient cancer therapy. Herein, six paclitaxel-citronellol conjugates are synthesized using either thioether bond, disulfide bond, selenoether bond, diselenide bond, carbon bond or carbon-carbon bond as linkages. These prodrugs can self-assemble into uniform nanoparticles with ultrahigh drug-loading capacity. Interestingly, sulfur/selenium/carbon bonds significantly affect the efficiency of prodrug nanoassemblies. The bond angles/dihedral angles impact the self-assembly, stability and pharmacokinetics. The redox-responsivity of sulfur/selenium/carbon bonds has remarkable influence on drug release and cytotoxicity. Moreover, selenoether/diselenide bond possess unique ability to produce reactive oxygen species, which further improve the cytotoxicity of these prodrugs. Our findings give deep insight into the impact of chemical linkages on prodrug nanoassemblies and provide strategies to the rational design of redox-responsive drug delivery systems for cancer therapy.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31324811 PMCID: PMC6642185 DOI: 10.1038/s41467-019-11193-x
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Schematic representation. Sulfur/selenium/carbon bond-bridged PTX–CIT prodrug nanoassemblies for cancer therapy
Fig. 2In vitro redox-responsive drug release. (a) 1 mM H2O2; (b) 10 mM H2O2; (c) 1 mM DTT; (d) 10 mM DTT. Data are presented as mean ± SD (three independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t test
Fig. 3Cytotoxicity assay and cellular uptake. Viability of KB cells after treated with various concentrations of Taxol and prodrug nanoassemblies for (a) 48 h and (b) 72 h. Data are presented as mean ± SD (three independent experiments). (c) Free PTX released from prodrug nanoassemblies after incubation with KB cells for 48 h. Data are presented as mean ± SD (three independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t test. (d) CLSM images of KB cells incubated with free coumarin-6 or coumarin-6-labeled prodrug nanoassemblies for 2 h. Scale bar represents 10 μm
Fig. 4Pharmacokinetic and in vivo biodistribution. (a) Molar concentration-time curves of the sum of released PTX and prodrugs. Data are presented as mean ± SD (five independent experiments). (b, c) In vivo biodistribution of Taxol and prodrug nanoassemblies at 1 h (b) and 4 h (c). (d) Tumor accumulation of Taxol and prodrug nanoassemblies. Data are presented as mean ± SD (three independent experiments). *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t test
Fig. 5In vivo antitumor efficacy of prodrug nanoassemblies. (a) Tumor volume. (b) Tumor burden. (c) Images of tumors. (d) Body weight changes. Data are presented as mean ± SD (five independent experiments). *P < 0.05, **P < 0.01 by two-tailed Student’s t test. (e) Hepatorenal function parameters. Data are presented as mean ± SD (three independent experiments). AST: aspartate aminotransferase (U L−1); ALT: alanine aminotransferase (U L−1), BUN: blood urea nitrogen (mmol L−1), CREA: creatinine (μmol L−1)